NCT05286242View on ClinicalTrials.gov

Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients

Active, not recruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions
Multiple SclerosisAutoimmune Blistering DiseaseB-Cell Deficiency
Interventions
BIOLOGICAL

COVID19 vaccine

All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.

Trial Locations (1)

06520

Yale University, New Haven

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Robert Leet and Clara Guthrie Patterson Trust

UNKNOWN

lead

Yale University

OTHER